TB-500 (Thymosin Beta-4 Fragment) – Research Compound Profile

TB-500 (Thymosin Beta-4 Fragment) – Research Compound Profile

Category: Tissue Regeneration | Molecular Type: Synthetic Peptide (43 amino acids) | Research Status: Phase I/II Clinical Trials (Thymosin β4); Preclinical (TB-500 Fragment)

This page compiles published research data for qualified researchers. TB-500 is sold exclusively as a research compound, has not been approved by the FDA for human consumption, and is not intended for human use or self-administration. Nothing on this page constitutes medical advice, diagnosis, or a treatment recommendation.

Purchase for Research →

Molecular Overview

TB-500 is a synthetic peptide corresponding to the biologically active region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein broadly involved in tissue repair, cell migration, and angiogenesis [1][2]. Thymosin beta-4 is one of the most abundant intracellular peptides, reported at high micromolar-to-submillimolar concentrations in various tissues including platelets, wound fluid, and the thymus, where it serves as the primary G-actin sequestering molecule [9]. The peptide retains the critical N-terminal active sequence Ac-LKKTETQ — the seven-amino-acid domain responsible for actin-binding and cell-migration properties [1][14].

TB-500 was first isolated and characterized through thymus gland research and has since become a subject of investigation across tissue repair, cardioprotection, neuroprotection, and anti-fibrotic applications. The parent compound, thymosin beta-4, has advanced through Phase I and Phase II clinical trials in humans, while TB-500 as a fragment peptide remains primarily in preclinical investigation [3][15][18].

Structurally, Tβ4 is an intrinsically disordered protein in solution that adopts an extended α-helical conformation only upon binding G-actin. It contains a single internal cysteine and no disulfide bonding partner, which is relevant both to its actin-binding chemistry and to its susceptibility to oxidative modification during handling — the physiologically active reduced form can convert to an oxidized sulfoxide species that retains a distinct anti-inflammatory profile but loses actin-sequestering activity [9].

Mechanism of Action

The regenerative cascade associated with TB-500 operates through several interconnected molecular pathways documented in published literature.

Actin Polymerization Regulation: By binding to monomeric G-actin at a 1:1 stoichiometric ratio, Tβ4 regulates actin polymerization dynamics — the molecular engine that drives cell motility, cytoskeletal reorganization, and tissue repair [2]. This actin-sequestering function was characterized by Goldstein et al. (2007) as fundamental to the peptide’s multi-functional regenerative properties [2].

ILK-Akt Survival Signaling: TB-500 activates integrin-linked kinase (ILK), which in turn phosphorylates the survival kinase Akt/protein kinase B — a critical anti-apoptotic signal that protects cells from programmed death following ischemic or traumatic injury. This ILK-Akt axis was first demonstrated by Bock-Marquette et al. (2004) in cardiac tissue, where Tβ4 administration in a mouse coronary artery ligation model was associated with improved myocardial cell survival and contractile function [7].

Angiogenesis Promotion: TB-500 potently stimulates angiogenesis — the growth of new blood vessels from pre-existing vasculature. In dermal wound models, Malinda et al. (1999) reported that topical Tβ4 produced a marked, statistically significant increase in endothelial cell migration compared to controls, accelerating granulation tissue formation and capillary bed development [1][15].

Anti-Inflammatory Modulation: Tβ4 exerts significant anti-inflammatory effects through multiple mechanisms. As documented by Xing et al. (2021), the oxidized form (Tβ4 sulfoxide) directly inhibits neutrophil chemotaxis, reducing inflammatory cell infiltration at wound sites, while the intact peptide decreases pro-inflammatory cytokine release and suppresses NF-κB activation [9][16].

Neurorestorative Properties: In embolic stroke models, Morris et al. (2014) demonstrated that Tβ4 administration in the acute post-occlusion window promoted oligodendrocyte progenitor cell (OPC) differentiation and myelination, with functional neurological improvement persisting through an extended observation period. The study identified an intermediate exposure level associated with the greatest neurological recovery, with markedly increased myelin basic protein immunoreactivity observed in the ischemic boundary zone at that exposure level relative to both lower and higher levels tested — consistent with a bell-shaped dose-response and a therapeutic ceiling [6].

Progenitor Cell Activation: TB-500 not only facilitates repair of existing damage through enhanced cell migration and survival but also activates endogenous progenitor cell populations. Smart et al. (2007) demonstrated that systemic Tβ4 re-activated dormant epicardial progenitor cells independently of injury in adult mice, thickening the epicardial layer and restoring an embryonic-like regenerative phenotype with increased capillary and vessel density [5][17].

Pharmacokinetics: TB-500 has a relatively short plasma half-life (estimated under 30 minutes based on doping-control analyses) but exerts prolonged tissue-level effects attributed to intracellular accumulation and sustained paracrine signaling [8][9].

Published Research Parameters

The following table indexes the study models, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

Stability & Storage Characteristics

Published data and standard peptide handling literature report the following stability characteristics for TB-500 and related thymosin beta-4 compounds:

• Lyophilized stability: The lyophilized (freeze-dried) form remains stable for 24+ months when stored at −20 °C (−4 °F) in a dry, dark environment protected from moisture.
• Solution stability: Once reconstituted, peptide solutions stored at 2–8 °C (35.6–46.4 °F) are generally reported to maintain stability for approximately 4 weeks (28 days) before appreciable degradation occurs.
• Freeze-thaw sensitivity: Repeated freeze-thaw cycles are documented to damage the peptide’s tertiary structure and reduce bioactivity. Reconstituted solutions should not be re-frozen.
• Light sensitivity: Stored protected from direct light and excessive vibration. Amber or foil-wrapped vials are standard in research settings.
• Thermal degradation: The peptide is sensitive to elevated temperatures; room-temperature exposure should be minimized for reconstituted solutions.
• Oxidative degradation: The single internal cysteine residue is the principal site of oxidative modification. Conversion to the sulfoxide form alters the peptide’s biological profile (loss of actin affinity, retained anti-chemotactic activity), making oxidation state a meaningful quality parameter distinct from simple purity [9].

Analytical Characterization

Because TB-500 is a mid-sized 43-residue peptide with a single oxidation-prone cysteine, analytical characterization should distinguish reduced from oxidized (sulfoxide) species in addition to establishing overall purity. Reverse-phase HPLC resolves the intact peptide from truncated synthesis byproducts and from the oxidized variant, which typically elutes with a shifted retention time. Electrospray or MALDI mass spectrometry confirms the intact monoisotopic mass and reveals a +16 Da shift characteristic of methionine or cysteine oxidation when present. A quantitative peptide-content assay (amino acid analysis or calibrated UV absorbance) is necessary to establish net peptide mass independent of counter-ion, residual trifluoroacetate, and moisture content in the lyophilizate. Certificates of analysis should report both purity by RP-HPLC and confirmed identity by mass spectrometry for each production lot.

Key Published Research Findings

All findings below are attributed to specific peer-reviewed publications. TB-500 and its parent compound thymosin beta-4 have been investigated across multiple therapeutic areas:

• Wound Healing: In a 1999 Journal of Investigative Dermatology study using a rat dermal wound model, Malinda et al. observed that Tβ4 significantly increased the rate of wound closure by enhancing keratinocyte and endothelial cell migration, with treated wounds showing markedly faster closure compared to controls [1][15].

• Cardioprotection: In a 2004 Nature study, Bock-Marquette et al. demonstrated that systemic Tβ4 administration following myocardial ischemia in mice produced a substantial reduction in infarct size and improved left ventricular ejection fraction, with benefits mediated through ILK/Akt-dependent anti-apoptotic signaling [7].

• Neurological Recovery: In a 2014 Journal of the Neurological Sciences dose-response study using a rat embolic stroke model, Morris et al. reported that intermediate Tβ4 exposure levels produced significant relative improvement across three functional neurological tests (adhesive removal, mNSS, foot fault) sustained from day 14 through day 56 post-stroke, while the highest tested exposure level showed no additional benefit — a pattern consistent with a therapeutic ceiling effect [6].

• Anti-Fibrotic Effects: Published research in hepatic and cardiac fibrosis models has documented that Tβ4 reduces scar tissue formation by modulating collagen deposition and preventing myofibroblast differentiation. Ho et al. (2011) demonstrated that Tβ4 upregulated antioxidant and anti-apoptotic genes in corneal epithelial cells [16], while separate studies in liver fibrosis models explored its anti-fibrotic potential [10].

• Epicardial Progenitor Activation: In a 2007 Nature study, Smart et al. demonstrated that systemic Tβ4 administration in adult mice re-activated dormant epicardial progenitor cells independently of injury, thickening the epicardial layer and restoring an embryonic-like regenerative phenotype with increased capillary and vessel density [5][17].

• Clinical Wound Healing Trials: In a 2012 review published in Annals of the New York Academy of Sciences, Kleinman and Sosne reported that topical Tβ4 accelerated wound healing rates in both preclinical animal models and human clinical trials (Phase II) for venous stasis and pressure ulcers, with treated patients showing improved wound-area reduction over an 84-day observation period [15][18].

Safety Profile in Published Literature

Phase I Human Trial Data:
In a randomized, placebo-controlled Phase I trial published in Annals of the New York Academy of Sciences (2010), Ruff et al. administered intravenous Tβ4 to healthy volunteers across a range of single and repeated-dose exposures. No serious adverse events or dose-limiting toxicities were reported across any exposure group studied [3].

• Headache was the most frequently reported adverse event, occurring at rates consistent with placebo and generally mild in severity [3].
• Mild upper respiratory infection symptoms were the second most common adverse event, again at rates comparable to placebo [3].

Preclinical Toxicology:

• Rodent 28-day toxicology studies established a favorable no-observed-effect exposure level well above the range associated with pharmacological activity [3][6].
• A parallel no-observed-effect finding was reported in beagle dog toxicology studies [3].
• In the dose-response stroke study by Morris et al. (2014), intermediate exposure levels demonstrated efficacy, while the highest level tested showed no additional benefit — suggesting a ceiling effect rather than emerging toxicity [6].

Limitations of Current Safety Data:

• Phase I data are derived from the parent compound thymosin beta-4 administered intravenously; the safety profile of the TB-500 fragment peptide via other routes has not been independently established in registered human clinical trials.
• Long-term human safety data beyond the observation window of published controlled trials are not available.

Regulatory Status

• FDA Approval: TB-500 is not approved by the FDA for human therapeutic use. The parent compound thymosin beta-4 has been investigated in Phase I and Phase II clinical trials but has not received FDA marketing authorization [3][18].
• Clinical Trials: A Phase IIa safety and efficacy study of thymosin beta-4 in patients with acute myocardial infarction has been registered (NCT05485818) [18]. Additional Phase II dermal wound trials have been conducted [15].
• WADA Status: TB-500 is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the S2 category (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) [13].
• Doping Control: Thomas et al. (2012) developed analytical methods for detecting TB-500 in urine as part of anti-doping efforts, reflecting the compound’s prohibited status in competitive athletics [8].
• Research Use Only: This compound is sold exclusively for research purposes and is not intended for human consumption, therapeutic application, or athletic performance enhancement.

References

1. Journal of Investigative Dermatology (1999) — Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta-4 accelerates wound healing. J Invest Dermatol. 113(3):364–368. View Source

2. Annals of the New York Academy of Sciences (2007) — Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. View Source

3. Annals of the New York Academy of Sciences (2010) — Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta-4 in healthy volunteers. Ann N Y Acad Sci. 1194:223–229. View Source

4. Neuroscience (2010) — Morris DC, Chopp M, Zhang L, Lu M, Zhang ZG. Thymosin beta-4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 169(2):674–682. View Source

5. Cells (2021) — Maar K, Hetenyi R, Maar S, et al. Utilizing developmentally essential secreted peptides such as thymosin beta-4 to remind the adult organs of their embryonic state—new directions in anti-aging regenerative therapies. Cells. 10(6):1343. View Source

6. Journal of the Neurological Sciences (2014) — Morris DC, Cui Y, Cheung WL, et al. A dose response study of thymosin β4 for the treatment of acute stroke. J Neurol Sci. 345(0):61–67. View Source

7. Nature (2004) — Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta-4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 432(7016):466–472. View Source

8. Journal of Chromatography A (2012) — Thomas A, Geyer H, Schänzer W, et al. Doping control analysis of TB-500, a synthetic thymosin β4 fragment, in urine. J Chromatogr A. View Source

9. Frontiers in Endocrinology (2021) — Xing Y, Ye Y, Zuo H, Li Y. Progress on the function and application of thymosin β4. Front Endocrinol. 12:767785. View Source

10. International Journal of Molecular Sciences (2016) — MDPI. Potential role of thymosin beta-4 in liver fibrosis. Int J Mol Sci. 16(5):10624–10643. View Source

11. World Anti-Doping Agency (WADA) — 2024 Prohibited List: S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics. TB-500 classification as prohibited substance. View Source

12. FASEB Journal (2010) — Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin β4 defined by active sites in short peptide sequences. FASEB J. View Source

13. Annals of the New York Academy of Sciences (2012) — Kleinman HK, Sosne G. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 1270:37–44. View Source

14. PLoS ONE (2011) — Ho JHC, Chuang CH, Ho CY, et al. Thymosin beta-4 prevents oxidative stress by targeting antioxidant and anti-apoptotic genes in corneal epithelial cells. PLoS ONE. 6(11):e26912. View Source

15. Nature (2007) — Smart N, Risebro CA, Melville AA, et al. Thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 445(7124):177–182. View Source

16. ClinicalTrials.gov — Safety and efficacy study of thymosin beta 4 in patients with acute myocardial infarction. Phase IIa study (NCT05485818). View Source

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. TB-500 (Thymosin Beta-4 Fragment) is sold exclusively as a research compound and has not been approved by the FDA for human consumption or use. TB-500 is classified as a prohibited substance by the World Anti-Doping Agency (WADA). All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

Purchase TB-500 for Research →